Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1837279 | 1.00 | HRH3 (0.58) | HRH3POLBKCNH2 | |
| SCHEMBL1831547 | 0.99 | HRH3 (0.57) | HRH3POLBKCNH2 | |
| SCHEMBL1831548 | 0.99 | HRH3 (0.57) | HRH3POLBKCNH2 | |
| SCHEMBL1834198 | 0.94 | HRH3 (0.56) | HRH3POLBKCNH2 | |
| SCHEMBL1834195 | 0.94 | HRH3 (0.56) | HRH3POLBKCNH2 | |
| SCHEMBL1833384 | 0.93 | HRH3 (0.56) | HRH3POLB | |
| SCHEMBL1833381 | 0.93 | HRH3 (0.56) | HRH3POLB | |
| SCHEMBL2743347 | 0.89 | HRH3 (0.57) | HRH3KCNH2 | |
| SCHEMBL1834062 | 0.89 | HRH3 (0.55) | HRH3 | |
| SCHEMBL1834060 | 0.89 | HRH3 (0.55) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322506-A1 | Histamine H3 receptor agents, preparation and therapeutic uses | Eli Lilly and Company (US) | 2011-05-18 | — | — | EP | claimed |
| US-20100160319-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | BEAVERS LISA SELSAM | 2010-06-24 | — | — | US | claimed |
| US-8008296-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008296-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008296-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2322506-A1 | Histamine H3 receptor agents, preparation and therapeutic uses | Eli Lilly and Company (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100160319-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | BEAVERS LISA SELSAM | 2010-06-24 | — | — | US | disclosed |
| US-20100160319-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | BEAVERS LISA SELSAM | 2010-06-24 | — | — | US | disclosed |
| US-20100160319-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | BEAVERS LISA SELSAM | 2010-06-24 | — | — | US | disclosed |
| WO-2007005503-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160319-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | HRH3 1/4885POLB 4414/4885KCNH2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.